Alnylam Pharmaceuticals, Inc. (ALNY)
ALNY moved a median of -0.07% 30 minutes after news, and -0.07% by the close. How ALNY actually reacts to news — the realized, point-in-time move the market made, measured across 664 labeled events over the last three years with zero look-ahead.
ALNY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.07% | 45% | 663 |
| 30-min | -0.07% | 48% | 664 |
| 60-min | -0.03% | 47% | 664 |
| to close | -0.07% | 49% | 660 |
| Middle 50% of ALNY reactions | -0.85% to +0.80% |
|---|---|
| Median reaction (30-min) | -0.07% |
| Measured reactions | 664 |
Half of all Alnylam Pharmaceuticals, Inc. news events land between -0.85% and +0.80% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ALNY reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 35 | +0.61% | 63% | +0.97% |
| Analyst downgrades | 26 | -0.10% | 46% | +0.43% |
| Coverage initiations | 31 | -0.20% | 45% | +0.75% |
| Rating reiterations | 262 | +0.04% | 52% | +0.42% |
| Price-target raises | 78 | +0.12% | 56% | +0.73% |
| Price-target cuts | 43 | -0.10% | 47% | +0.27% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how ALNY ranks against every other measured name →
That’s how ALNY usually reacts — get an email when it moves on news →Email me when ALNY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ALNY's baseline. Nothing else.
Recent ALNY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM | Press release | Business Wire | +0.16% | -0.31% | |
| Alnylam to Webcast Presentations at Upcoming September Investor Conferences | Press release | Business Wire | +3.82% | +8.49% | |
| Singapore is the first ASEAN country to provide government subsidy for eligible patients receiving vutrisiran for transthyretin amyloidosis | Press release | PR Newswire | +0.70% | +2.33% | |
| Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings | Press release | Business Wire | +0.62% | +2.22% | |
| Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026 | Press release | Business Wire | -0.99% | +0.08% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alnylam Pharmaceuticals, Inc. (ALNY) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.16% | -0.51% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alnylam Pharmaceuticals, Inc. (ALNY) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.37% | +1.55% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.02% | +1.06% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Alnylam Pharmaceuticals, Inc. (ALNY) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.00% | — | |
| Alnylam Pharmaceuticals, Inc. (ALNY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.10% | +2.04% | |
| ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law | Press release | PR Newswire | +0.51% | +3.15% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Alnylam Pharmaceuticals, Inc. (ALNY) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.17% | +0.89% | |
| Alnylam Pharmaceuticals, Inc. (ALNY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.08% | +0.65% | |
| ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law | Press release | Business Wire | +0.69% | -0.60% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alnylam Pharmaceuticals, Inc. (ALNY) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.12% | +1.70% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Alnylam Pharmaceuticals, Inc. (ALNY) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +1.79% | +5.48% | |
| Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress | Press release | Business Wire | -1.62% | -8.27% | |
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.62% | -8.27% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | -1.62% | -8.27% | |
| Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results | Press release | Business Wire | -0.64% | +2.11% | |
| Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease | Press release | Business Wire | -0.51% | -0.91% | |
| Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform | Press release | Business Wire | -0.01% | -0.17% | |
| Alnylam to Host Tenth “RNAi Roundtable” Webcast Series | Press release | Business Wire | -1.26% | -2.11% | |
| GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region | Press release | Business Wire | -0.90% | -2.17% | |
| Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics | Press release | Business Wire | -0.36% | +2.16% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: May 20 | SEC filing · Form 8-K | SEC EDGAR | +1.04% | +4.12% | |
| Alnylam Issues 2025 Corporate Responsibility Report | Press release | Business Wire | -0.09% | +1.83% | |
| New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden | Press release | Business Wire | +0.12% | +1.17% | |
| Alnylam to Webcast Presentations at Upcoming Investor Conferences | Press release | Business Wire | -0.12% | -1.54% | |
| Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM | Press release | Business Wire | -1.62% | -0.73% | |
| Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress | Press release | Business Wire | -3.62% | +0.65% | |
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.62% | +0.65% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | -3.62% | +0.65% | |
| Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results | Press release | Business Wire | -0.85% | -3.98% | |
| Form ARS ALNYLAM PHARMACEUTICALS, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.42% | +0.01% | |
| Form DEF 14A ALNYLAM PHARMACEUTICALS, For: May 20 | SEC filing · Form DEF | SEC EDGAR | -1.42% | +0.01% | |
| Form DEFA14A ALNYLAM PHARMACEUTICALS, | SEC filing · Form DEFA14A | SEC EDGAR | -1.42% | +0.01% | |
| New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management | Press release | Business Wire | -0.23% | -1.09% | |
| Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association | Press release | Business Wire | +0.65% | +1.53% | |
| Alnylam to Webcast TTR Investor Webinar | Press release | Business Wire | -0.33% | -0.99% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | -0.98% | |
| Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference | Press release | Business Wire | -0.15% | -1.26% | |
| Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress | Press release | Business Wire | -1.57% | -1.89% | |
| Form 10-K ALNYLAM PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.57% | -1.89% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | -1.57% | -1.89% | |
| Form S-8 ALNYLAM PHARMACEUTICALS, | SEC filing · Form S-8 | SEC EDGAR | +1.33% | +3.92% | |
| Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results | Press release | Business Wire | -0.51% | -0.74% | |
| Form 8-K ALNYLAM PHARMACEUTICALS, For: Jan 11 | SEC filing · Form 8-K | SEC EDGAR | -3.52% | -1.83% | |
| Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact | Press release | Business Wire | -3.52% | -1.83% | |
| Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | -0.07% | +0.07% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ALNY section they belong to.
Where else ALNY is measured.
ALNY earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ENDOCYTE (ECYT) | 671 | -0.08% | 46% |
| PolarityTE, Inc. (PTE) | 670 | -0.62% | 38% |
| UroGen Pharma Ltd. - Ordinary Shares (URGN) | 664 | +0.13% | 53% |
| Brainstorm Cell Therapeutics Inc. (BCLI) | 660 | 0.00% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Alnylam Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled ALNY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 664 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of ALNY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ALNY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.